AG
AGEN.US Agenus Inc
- Market cap
- USD 311M
- P/E
- 29.9x
- P/B
- 218.61x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AGEN.US undervalued?
Graham numberThe Graham number of Agenus Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Agenus Inc fundamental analysis
No fundamental analysis for Agenus Inc yet.
Agenus Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) b…
Full company profileAgenus Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Agenus Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 22.6M | 42.9M | 36.8M | 150M | 88.2M | 296M | 98.0M | 156M | 103M | 114M | 133M |
| Gross Profit | -72.4M | -73.2M | -87.8M | -18.3M | -56.8M | 114M | -99.2M | -81.4M | -52.6M | 33.8M | 133M |
| Operating Income | -107M | -104M | -124M | -70.1M | -117M | 25.7M | -179M | -160M | -120M | -20.6M | 50.3M |
| EBITDA | -105M | -95.8M | -130M | -63.4M | -115M | 43.8M | -162M | -146M | -101M | 62.2M | 113M |
| Net Income | -127M | -121M | -160M | -108M | -181M | -23.9M | -220M | -246M | -227M | 115K | 55.2M |
| EPS | -29 | -25 | -29 | -16 | -21 | -2.09 | -16 | -14 | -11 | 0.00 | 0.66 |
| Balance Sheet | |||||||||||
| Total Assets | 157M | 138M | 136M | 155M | 215M | 466M | 414M | 314M | 226M | 227M | 246M |
| Total Liabilities | 196M | 214M | 311M | 387M | 426M | 418M | 468M | 462M | 533M | 505M | 358M |
| Shareholders' Equity | -39.1M | -75.8M | -175M | -231M | -211M | 47.9M | -54.9M | -148M | -326M | -271M | -105M |
| Cash & Short-term Investments | 76.4M | 60.2M | 53.1M | 61.8M | 99.9M | 307M | 193M | 76.1M | 40.4M | 3.00M | 66.9M |
| Total Debt | 131M | 163M | 13.4M | 23.4M | 55.7M | 58.3M | 78.4M | 350M | 94.9M | 335M | 39.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -80.0M | -94.2M | -131M | -18.7M | -139M | 10.1M | -175M | -224M | -158M | -158M | -116M |
| Capital Expenditure | 12.5M | 3.12M | 3.60M | 4.66M | 3.47M | 33.8M | 53.1M | 9.95M | 576K | 576K | 0.00 |
| Free Cash Flow | -92.5M | -97.3M | -135M | -23.3M | -143M | -23.7M | -228M | -234M | -159M | -159M | -116M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -49.9% | - | - | - | - | - |
| ROA | -80.9% | -87.2% | -117.1% | -69.3% | -84.3% | -5.1% | -53.2% | -78.3% | -100.4% | 0.1% | 22.5% |
| Net Profit Margin | -562.6% | -281.5% | -434.1% | -71.7% | -205.2% | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% | 41.5% |
| Debt to Equity | - | - | - | - | - | 1.22x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Agenus Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 9.13M | 0.80 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 16.0M | 3.25 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Apr 12, 2024.
Who owns Agenus Inc
- Insiders 6.24%
- Institutions 44.11%
- Public & others 49.66%
- Shares outstanding 45.2M
- Free float 40.5M
Top funds holding AGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.26M | 2.78% | +7.41% | Sep 2026 |
| iShares Russell 2000 ETF | 965K | 2.14% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 512K | 1.13% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 442K | 0.98% | +1.43% | Aug 2026 |
| iShares Russell 2000 Value ETF | 314K | 0.70% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 291K | 0.64% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 223K | 0.49% | -2.50% | Sep 2026 |
| Fidelity Extended Market Index | 167K | 0.37% | -17.16% | Sep 2026 |
| First Trust Dow Jones Sel MicroCap ETF | 153K | 0.34% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 115K | 0.25% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 96.3K | 0.21% | 0.00% | Sep 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 94.6K | 0.21% | -53.93% | Sep 2026 |
| Vanguard VIF Small Co Gr | 91.5K | 0.20% | -20.28% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 82.7K | 0.18% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 81.2K | 0.18% | -0.05% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 76.9K | 0.17% | +252.27% | Aug 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 68.9K | 0.15% | -7.47% | Sep 2026 |
| Fidelity Series Total Market Index | 55.4K | 0.12% | -14.01% | Sep 2026 |
| Fidelity Small Cap Value Index | 50.1K | 0.11% | +2.58% | Aug 2026 |
Top institutions holding AGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 2.56M | 5.68% | +370.05% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.68M | 3.71% | +16.38% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.43M | 3.16% | +19.45% | Jun 2026 |
| Siren, L.L.C. | 1.06M | 2.36% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.04M | 2.29% | +197.09% | Jun 2026 |
| Mackenzie Investments | 714K | 1.58% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 448K | 0.99% | +1,325.52% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 440K | 0.97% | -36.12% | Jun 2026 |
| GlobeFlex Capital, L.P. | 419K | 0.93% | 0.00% | Jun 2026 |
| State Street Corp | 412K | 0.91% | +164.04% | Jun 2026 |
| Man Group PLC | 340K | 0.75% | +22.02% | Jun 2026 |
| Northern Trust Corp | 314K | 0.70% | +250.04% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 310K | 0.69% | +56.19% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 272K | 0.60% | +35.47% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 262K | 0.58% | -11.41% | Jun 2026 |
| Renaissance Technologies Corp | 228K | 0.51% | -20.06% | Jun 2026 |
| Panagora Asset Management Inc | 180K | 0.40% | +10.08% | Jun 2026 |
| Susquehanna Portfolio Strategies LLC | 159K | 0.35% | 0.00% | Jun 2026 |
| Jump Financial LLC | 104K | 0.23% | -33.85% | Jun 2026 |
| Bank of New York Mellon Corp | 102K | 0.23% | 0.00% | Jun 2026 |
Agenus Inc company profile
- Company name
- Agenus Inc
- Ticker
- AGEN.US
- Exchange
- USA Stocks
- Listed since
- Feb 4, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Fiscal year end
- December
- Address
- 3 Forbes Road, Lexington, MA, United States, 02421-7305
- Phone
- 781 674 4400
- Website
- agenusbio.com
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Agenus Inc management
10- Dr. Garo H. Armen Ph.D.Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman · born 1953
- Dr. Steven J. O'Day M.D., Ph.D.Chief Medical Officer · born 1961
- Dr. Jennifer S. Buell Ph.D.Director and President & CEO of MiNK Therapeutics · born 1975
- Craig WinterChief Information Officer
- Mr. Zack ArmenVice President of Investor Relations & Corporate Development
- Ms. Stefanie Perna-NacarChief Communications & Government Relations Officer
- Ms. Tracy Mazza ClementeChief People Officer
- Dr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic Advisor
- Dr. Robin G. Taylor M.B.A., Ph.D.Chief Commercial Officer
- Dr. Kamel Djazouli M.D.Head of Medical Affairs